Konsultbolag slås ihop – Scandinavian CRO och Qadvis blir Aurevia

Scandinavian CRO och Qadvis har nu bägge officiellt blivit en del av Aurevia, och tar därmed det nya bolagets namn.

Sahlgrenska Science Park

Jan Holmgren to receive award for the development of cholera vaccine

Researcher Jan Holmgren is being awarded for the development of the first effective drinkable cholera vaccine. The award is given by the International Vaccine I...

The Crucial Role of Core Imaging Facility Managers

User story from ZEISS and the University of York.

Galenica AB

Metabolon

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

Meribel Pharma Solna

Medicon Valley Alliance

Bio-Works

Lonza

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

JMP Statistical Discovery

Kokainberoende råttor knarkade mindre med semaglutid

Läkemedel som innehåller semaglutid minskade suget hos kokainberoende råttor i en studie från Göteborgs universitet.

Mercodia AB

Merck Life Science A/S

Pharma Relations AB

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

ProPharma

Kompauto Nordic AB

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

Acquisition of consulting company Key2Compliance

The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...